China Resources Beer (Holdings) Company Limited (0291.HK)

Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI)

Company announcement – No. 4 / 2022 Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI) Top-line results expected in the second quarter of 2022Pending positive results, Zealand intends to file for marketing approval with the US Food and Drug Administration Copenhagen, DK and Boston, MA, U.S. February 15, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and